Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, November 2021 - March 2022
View ORCID ProfileFrancesco Branda
doi: https://doi.org/10.1101/2022.04.21.22273567
Francesco Branda
1Department of Computer Science, Modeling, Electronics and Systems Engineering (DIMES), University of Calabria, Rende, Italy
Posted April 27, 2022.
Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, November 2021 - March 2022
Francesco Branda
medRxiv 2022.04.21.22273567; doi: https://doi.org/10.1101/2022.04.21.22273567
Subject Area
Subject Areas
- Addiction Medicine (326)
- Allergy and Immunology (642)
- Anesthesia (170)
- Cardiovascular Medicine (2452)
- Dermatology (208)
- Emergency Medicine (384)
- Epidemiology (11896)
- Forensic Medicine (10)
- Gastroenterology (707)
- Genetic and Genomic Medicine (3828)
- Geriatric Medicine (356)
- Health Economics (646)
- Health Informatics (2470)
- Health Policy (954)
- Hematology (348)
- HIV/AIDS (806)
- Medical Education (379)
- Medical Ethics (105)
- Nephrology (409)
- Neurology (3595)
- Nursing (202)
- Nutrition (536)
- Oncology (1865)
- Ophthalmology (544)
- Orthopedics (227)
- Otolaryngology (293)
- Pain Medicine (235)
- Palliative Medicine (68)
- Pathology (457)
- Pediatrics (1057)
- Primary Care Research (432)
- Public and Global Health (6259)
- Radiology and Imaging (1317)
- Respiratory Medicine (842)
- Rheumatology (387)
- Sports Medicine (332)
- Surgery (418)
- Toxicology (51)
- Transplantation (177)
- Urology (149)